Zhang et al. have developed dual IDO1/TDO inhibitors for treating inflammation-induced depression by inhibiting microglial cell activation, decreasing IDO1 expression, and decreasing pro-inflammatory cytokine and kynurenine levels in the mouse brain [117]. Here, TDO2 is linked to depressive symptom measurement.